Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CORT
- Rev/Share 6.878
- Book/Share 6.1069
- PB 11.5509
- Debt/Equity 0.0104
- CurrentRatio 3.063
- ROIC 0.1641
- MktCap 7432940880.0
- FreeCF/Share 1.7316
- PFCF 41.2302
- PE 55.4196
- Debt/Assets 0.0082
- DivYield 0
- ROE 0.201
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Read More
CORT's Q4 Earnings and Revenues Fall Short of Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
Read More
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Joe Belanoff - Co-Founder, President, CEO & Director Bill Guyer - Chief Development Officer Sean Maduck - President, Endocrinology Conference Call Participants David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Asim Rana - Truist Operator Thank you for standing by, and welcome to Corcept Therapeutics conference call.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500